Webinar 0.5 CPD hrsSGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney DiseaseDiabetes / MetabolicSGLT2 inhibitors started as diabetes drugs and became some of the most important medicines in cardiology and nephrology.… 📅 05 Apr 2026 Watch Webinar →
Webinar 0.5 CPD hrsGLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular RevolutionDiabetes / MetabolicGLP-1 agonists have transformed the treatment of type 2 diabetes and obesity. In this episode, Dr Anzal Qurbain… 📅 05 Apr 2026 Watch Webinar →
Podcast 00:15:32GLP-1 Agonists: Semaglutide, Tirzepatide and the Cardiovascular RevolutionDiabetes / MetabolicGLP-1 agonists have transformed the treatment of type 2 diabetes and obesity. In this episode, Dr Anzal Qurbain… 📅 03 Apr 2026 Listen →
Podcast 00:14:06SGLT2 Inhibitors: From Glycaemia to Heart Failure and Chronic Kidney DiseaseDiabetes / MetabolicSGLT2 inhibitors started as diabetes drugs and became some of the most important medicines in cardiology and nephrology.… 📅 03 Apr 2026 Listen →
CPD Module Intermediate 1.5 CPD hrsNICE NG28: Type 2 Diabetes in Adults — 2024 UpdateDiabetes / MetabolicCPD module on NICE NG28 type 2 diabetes updates, including SGLT2/GLP-1 therapy selection, HbA1c targets, renal and cardiovascular… 📅 25 Mar 2026 Start Module →
CPD Module Advanced 1.5 CPD hrsCardiovascular Risk Reduction — Latest Evidence 2024Cardiology / CardiovascularAdvanced CPD on cardiovascular risk reduction, covering QRISK3, statin intensification, ezetimibe, PCSK9 inhibitors, inclisiran and monitoring. 📅 25 Mar 2026 Start Module →